Lovo-Cel ‘Life-Changing, Transformative’ in Sickle Cell Disease
Meeting Coverage > > ASH: Hematology-- Near total resolution of discomfort occasions in clients, consisting of teenagers
by Mike Bassett, Staff Writer, MedPage Today December 10, 2023
SAN DIEGO-- A one-time treatment with lovotibeglogene autotemcel (Lyfgenia, lovo-cel) attained near total resolution of serious discomfort crises in clients with sickle cell illness (SCD) in an analysis provided here.
Of 34 evaluable clients, 88.2% (95% CI 72.5-96.7) attained total resolution of all vaso-occlusive occasions (VOEs) and 94.1% (95% CI 80.3-99.3) experienced total resolution of extreme VOEs throughout a 6 to 18 month evaluation duration following lovo-cel infusion, report...